TECP
FDMT icon

Trails Edge Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Trails Edge Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6M Buy
2,227,917
+925,000
+71% +$9.01M 4.7% 5
2026
Q1 		$12.1M Buy
+1,302,917
New +$11.3M 2.78% 15

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trails Edge Capital Partners's FDMT Position: Q2 2026 in Review

Trails Edge Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 71% in Q2 2026, buying an estimated $9.01M and bringing the position to 2,227,917 shares worth $29.6M. The position accounts for 4.7% of the portfolio, ranked #5.

Trails Edge Capital Partners first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Trails Edge Capital Partners held 2,227,917 shares of 4D Molecular Therapeutics worth $29.6M as of Q2 2026.
  • Trails Edge Capital Partners bought 925,000 4D Molecular Therapeutics shares in Q2 2026, an estimated $9.01M.
  • 4D Molecular Therapeutics made up 4.7% of Trails Edge Capital Partners's portfolio in Q2 2026, its #5 holding.
  • Trails Edge Capital Partners first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.